Plus Therapeutics Inc (PSTV) concluded trading on Thursday at a closing price of $1.44, with 345.99 million shares of worth about $498.23 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -4.64% during that period and on March 06, 2025 the price saw a gain of about 311.43%. Currently the company’s common shares owned by public are about 5.90M shares, out of which, 5.75M shares are available for trading.
Stock saw a price change of 113.33% in past 5 days and over the past one month there was a price change of 15.20%. Year-to-date (YTD), PSTV shares are showing a performance of 25.22% which decreased to -32.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.24 but also hit the highest price of $2.67 during that period. The average intraday trading volume for Plus Therapeutics Inc shares is 174.27K. The stock is currently trading 40.91% above its 20-day simple moving average (SMA20), while that difference is up 28.36% for SMA50 and it goes to -1.04% lower than SMA200.
Plus Therapeutics Inc (NASDAQ: PSTV) currently have 5.90M outstanding shares and institutions hold larger chunk of about 11.50% of that.
The stock has a current market capitalization of $8.48M and its 3Y-monthly beta is at 1.00. It has posted earnings per share of -$2.24 in the same period. It has Quick Ratio of 0.44. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PSTV, volatility over the week remained 95.47% while standing at 30.41% over the month.
Analysts are in expectations that Plus Therapeutics Inc (PSTV) stock would likely to be making an EPS of -0.51 in the current quarter, while forecast for next quarter EPS is -0.5 and it is -2.1 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.58 which is -0.43 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.7 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 47.88% while it is estimated to increase by 25.79% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on January 25, 2021 offering a Buy rating for the stock and assigned a target price of $8 to it. Coverage by Maxim Group stated Plus Therapeutics Inc (PSTV) stock as a Buy in their note to investors on October 16, 2020, suggesting a price target of $6 for the stock.
